ΔF508-CFTR correctors: Synthesis and evaluation of thiazole-tethered imidazolones, oxazoles, oxadiazoles, and thiadiazoles
作者:Long Ye、Bao Hu、Faris El-Badri、Brandi M. Hudson、Puay-Wah Phuan、A.S. Verkman、Dean J. Tantillo、Mark J. Kurth
DOI:10.1016/j.bmcl.2014.09.067
日期:2014.12
The most common mutation causing cystic fibrosis (CF) is deletion of phenylalanine residue 508 in the cystic fibrosis transmembrane regulator conductance (CFTR) protein. Small molecules that are able to correct the misfolding of defective ΔF508-CFTR have considerable promise for therapy. Reported here are the design, preparation, and evaluation of five more hydrophilic bisazole analogs of previously
引起囊性纤维化(CF)的最常见突变是删除囊性纤维化跨膜调节剂电导(CFTR)蛋白中的苯丙氨酸残基508。能够纠正有缺陷的ΔF508-CFTR的错误折叠的小分子具有治疗的巨大希望。本文报道的是先前鉴定出的Bithiazole CF校正剂1的另外五种亲水性双唑类似物的设计,制备和评估。。有趣的是,并没有通过引入更多的H键受体(O或N)来提高双唑ΔF508-CFTR校正剂的活性,但其与整体双唑分子的几何形状最相关。结构活性数据以及分子建模表明,活性双唑校正剂采用U形构象,校正剂活性取决于分子访问此分子几何结构的能力。